Cartesian Therapeutics, Inc. (RNAC) Total Assets by Year
Cartesian Therapeutics, Inc. closed fiscal year 2025 with $296.4M in total assets, $422.7M in total liabilities and -$126.2M in shareholder equity. Total assets fell 31.9% from the prior fiscal year. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Cartesian Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
RNAC Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $296.4M-31.9% | $435.0M+42.6% | $305.1M+83.9% | $165.9M+3.8% | $159.9M-3.4% | $165.4M+66.2% | $99.6M+123.8% | $44.5M-56.0% | $101.1M+13.2% | $89.3M+108.5% | $42.8M | N/A |
| Total Liabilities | $422.7M-4.3% | $441.8M-40.7% | $745.2M+934.2% | $72.1M-47.5% | $137.4M-25.1% | $183.4M+101.2% | $91.2M+82.7% | $49.9M+1.2% | $49.3M+43.5% | $34.3M-78.4% | $159.3M | N/A |
| Total Equity | -$126.2Mn/m | -$6.8Mn/m | -$440.2M-569.1% | $93.8M+316.6% | $22.5Mn/m | -$18.0M-314.4% | $8.4Mn/m | -$5.4M-110.5% | $51.8M-5.7% | $55.0Mn/m | -$116.5Mn/m | -$87.8M |
RNAC Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $318.6M-18.1% | $288.4M-29.5% | $296.4M-31.9% | $372.7M-18.2% | $388.9M+11.8% | $409.1M+25.8% | $435.0M+42.6% | $455.3M+329.4% | $347.7M+149.3% | $325.2M+108.9% | $305.1M+83.9% | $106.0M-40.5% |
| Total Liabilities | $443.9M+13.4% | $436.5M+1.3% | $422.7M-4.3% | $408.5M-10.1% | $391.4M-12.9% | $430.9M-2.5% | $441.8M-40.7% | $454.6M+894.6% | $449.2M+506.5% | $442.0M+444.9% | $745.2M+934.2% | $45.7M-51.0% |
| Total Equity | -$125.2Mn/m | -$148.1Mn/m | -$126.2Mn/m | -$35.8M-4866.5% | -$2.5Mn/m | -$21.8Mn/m | -$6.8Mn/m | $752K-98.8% | -$101.5M-255.0% | -$116.8M-256.6% | -$440.2M-569.1% | $60.3M-28.9% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Cartesian Therapeutics, Inc. financials
Frequently Asked Questions
What was Cartesian Therapeutics, Inc.'s total assets in fiscal year 2025?
Cartesian Therapeutics, Inc. closed fiscal year 2025 with $296.4M in total assets, $422.7M in total liabilities and -$126.2M in shareholder equity.
How fast is Cartesian Therapeutics, Inc.'s total assets growing?
Cartesian Therapeutics, Inc. (RNAC) total assets fell by 31.9% year over year, from $435.0M to $296.4M in fiscal year 2025.
What was Cartesian Therapeutics, Inc.'s total assets in the most recent quarter?
Cartesian Therapeutics, Inc. (RNAC) reported $318.6M in total assets in Q2 2026. This represents a decrease of 18.1% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Cartesian Therapeutics, Inc. (RNAC) reported on that line in every period on record.